Ecommerce Players Can’t Sell Specified Ayurvedic, Unani Drugs Without Prescription: CCPA
The sale or facilitating the sale of such specified drugs shall be done only after a valid prescription of a registered practitioner is uploaded on the platform: CCPA
The CCPA said that necessary action under the provisions of the Consumer Protection Act, 2019 can be taken if the legal framework is violated
The consumer watchdog said that consuming such drugs without medical supervision could lead to severe health complications
The Central Consumer Protection Authority (CCPA) on Thursday (July 14) issued an advisory to ecommerce platforms directing them to ensure that the sale of certain Ayurvedic, Siddha and Unani drugs is only done against valid prescription.
“The CCPA has issued an advisory to ecommerce entities concerning the sale of Ayurvedic, Siddha and Unani drugs containing ingredients listed in Schedule E(1) of the Drugs and Cosmetics Rules, 1945,” the advisory said.
The CCPA further said, “Ecommerce platforms have been advised that the sale or facilitating the sale of such drugs shall be done only after a valid prescription of a registered Ayurveda, Siddha or Unani practitioner respectively is uploaded by the user on the platform.”
The consumer watchdog said that consuming such drugs without medical supervision could lead to severe health complications.
Schedule E(1) of the Drugs and Cosmetics Rules, 1945 refers to the list of ‘poisonous substances’ under the Ayurvedic, Siddha and Unani systems of medicine and include items such as cannabis sativa, snake poison, arsenic, among others. Recommended For You: “The Central Authority may initiate necessary action under the provisions of the Consumer Protection Act, 2019 if, after investigation, it is found that the said drugs are offered for sale by any ecommerce platform in violation to the legal framework governing sale of such drugs to consume,” noted the advisory.Reiterating the rules, the advisory also specified that the container containing the said substances should be labelled […]
Click here to view original web page at inc42.com
I am a robot. This article is curated from another source (e.g. videos, images, articles, etc.). For the complete article please use the link provided to visit the original source or author. Content from other websites behaves in the exact same way as if the visitor has visited the other website.
Warning: The views and opinions expressed are those of the authors and do not necessarily reflect the official policy or position of MichelPaquin.com.